Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) revealed on Monday that it has opened the first clinical site for its Phase I trial of HG-CT-1, a CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia (R/R AML) in adults. Patient recruitment has now commenced.
The trial, designed as a dose-escalation study, aims to evaluate the safety profile of HG-CT-1 in R/R AML patients. Key secondary objectives include assessing the therapy's impact on efficacy, overall survival (OS), progression-free survival (PFS), and duration of response (DoR) in patients who achieve clinical responses.
AML is a particularly aggressive form of leukemia with poor survival rates, and existing treatments are limited. HG-CT-1 offers a promising alternative, harnessing CAR-T therapy to modify a patient's T-cells to target cancer cells.
The initiation of this trial marks a significant milestone for Hemogenyx Pharmaceuticals, advancing its lead asset into clinical testing at a renowned cancer research institution. The company is headquartered in London and has US operations in New York City, focusing on innovative treatments for blood and autoimmune diseases.
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
BioArctic secures European substance patent for Parkinson's drug candidate exidavnemab
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
1Cell.Ai launches OncoIncytes multi-modal cancer diagnostic panel
Viatris seeks Japanese approval for Effexor for generalised anxiety disorder
Kelun-Biotech's SKB518 granted IND clearance by US FDA
WuXi Biologics completes PPQ campaign at 15,000L production line in Hangzhou
SparX to present Phase 1 clinical update during AACR 2025
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
Clario partners with AWS on advancing clinical data analysis with generative AI
Mezzion Pharmaceuticals welcomes dedicated ICD-10 diagnosis codes for Fontan-associated conditions
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025